A practical reference on fatty acid oxidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-09 and is reviewed periodically as new material appears.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
ADP + phosphate + NADPH In humans, this enzyme is encoded by the gene NAXD. This enzyme belongs to the family of lyases, specifically the hydro-lyases, which cleave carbon-oxygen bonds. The systematic name of this enzyme class is (6S)-6-β-hydroxy-1,4,5,6-tetrahydronicotinamide-adenine-dinucleotide hydro-lyase (ATP-hydrolysing; NADH-forming). Other names in common use include reduced nicotinamide adenine dinucleotide hydrate dehydratase, ATP-dependent H4NAD(P)+OH dehydratase, (6S)-β-6-hydroxy-1,4,5,6-tetrahydronicotinamide-adenine-, and dinucleotide hydro-lyase (ATP-hydrolysing).
The better way of removing ammonium sulfate from the protein is mixing the precipitate protein in a buffer containing a mixture of SDS, Tris-HCl, and phenol and centrifuging the mixture. The precipitate that comes out of this centrifugation will contain salt-less concentrated protein.
Campbell and Satoshi Ōmura; she received it "for her discoveries concerning a novel therapy against Malaria". 2015: American inventor and clean water advocate Deepika Kurup invented a photocatalytic composite material that removes 100% of faecal coliform bacteria from contaminated water. Deepika won the Discovery Education 3M Young Scientist Challenge award and The US Stockholm Junior Water Prize for her work. 2015: Asha de Vos became the first Sri Lankan person to receive a PhD in marine mammal research, completing her thesis on "Factors influencing blue whale aggregations off southern Sri Lanka" at the University of Western Australia. 2016: American geophysicist Marcia McNutt became the first female president of the American National Academy of Sciences. 2016: French-Algerian particle physicist Yasmine Amhis was awarded the Jacques Herbrand Prize given by the French Academy of Sciences 2018: British astrophysicists Hiranya Peiris and Joanna Dunkley and Italian cosmologist Licia Verde were among 27 scientists awarded the Breakthrough Prize in Fundamental Physics for their contributions to "detailed maps of the early universe that greatly improved our knowledge of the evolution of the cosmos and the fluctuations that seeded the formation of galaxies". 2018: British astrophysicist Jocelyn Bell Burnell received the special Breakthrough Prize in Fundamental Physics for her scientific achievements and "inspiring leadership", worth $3 million.
16 February – Former footballer Ciaran Dickson is sentenced to six years in prison by the High Court in Glasgow for the hit-and-run killing of Aidan Pilkington in September 2021, when he was more than three times over the drink drive limit. Scotland is to scrap its Super 6 rugby series and reinstate a national "A team" as part of a comprehensive restructuring programme. 17 February – Delegates at the Scottish Labour Party conference pass a resolution calling for an immediate ceasefire in Gaza. Two men are killed in a road traffic accident involving three cars on the B9077 in Maryculter, Aberdeenshire. 20 February – Heather Woodbridge, aged 29, is appointed as leader of Orkney Islands Council, becoming Scotland's youngest council leader and the first woman to lead Orkney Islands Council. The BBC announces plans to reshape the BBC Scotland TV channel, including axing the hour-long news programme The Nine and replacing it with a 30-minute programme. 22 February – Argyll and Bute Council votes to raise its council tax by 10%, and rejects the Scottish Government's council tax freeze by doing so. 23 February – The Scottish Government publishes draft legislation proposing a ban on the sale of disposable vapes in Scotland by 1 April 2025. 24 February – Police Scotland begins an investigation after burnt human remains are found near Motherwell Football Club. 25 February – The Scottish Government confirms that Economy Secretary Màiri McAllan, who is pregnant, will take maternity leave during the summer, becoming the second Scottish Government minister to do so.
Sources: en.wikipedia.org
=== Etymology === Obesity is from the Latin obesitas, which means "stout, fat, or plump". Ēsus is the past participle of edere (to eat), with ob (over) added to it. The Oxford English Dictionary documents its first usage in 1611 by Randle Cotgrave.
===== Group D2 – Labile prodrug esters ===== Ciclesonide, cortisone acetate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone buteprate, hydrocortisone butyrate, hydrocortisone valerate, prednicarbate, and tixocortol pivalate.
=== Autoimmune === Lichen planus: A chronic inflammatory disease with different forms of oral presentations. The most classic appearance of lichen planus is the presence of white streaks in inner cheek, tongue, and gum. Desquamative gingivitis can be seen in patients with lichen planus. Biopsy is done for definitive diagnosis of lichen planus. Graft-versus-host disease: An autoimmune disease developed following bone marrow transplant in which its oral presentation is similar to lichen planus. Pemphigus vulgaris: An autoimmune chronic disease with clinical presentation of formation of superficial and large blisters which then burst into ulcers on the skin or mucous membrane. Mucous-membrane pemphigoid: Autoimmune disease which affects only mucous membranes with clinical presentation of hard and rigid blisters which then rupture eventually into deep ulcers. Cutaneous lupus erythematosus: These present as oral discoid lesions which may be present on the inner cheek and behind the lips. White papules may also be present.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.